feito do extrato da Passiflora edulis adjuvante à insulina na doença renal diabética: avaliação da megalina como biomarcador urinário

Abstract

Diabetic kidney disease (DKD) is a chronic complication of type 1 diabetes mellitus (T1DM), requiring adequate glycemic control for its prevention. Insulin is the main treatment for T1DM, but maintaining adequate glycemic control is a challenge. Thus, the present study aims to investigate, in a non-clinical model, the effect of hydroethanolic extract of Passiflora edulis (EHPE) adjuvant to insulin, using megalin as a potential early urinary biomarker of kidney injury. Thirty-seven Wistar rats with T1DM induced by streptozotocin were used, divided into four groups: control (CTL), diabetic (D), insulin-treated (DI) and insulin+EHPE-treated. Biochemical parameters such as blood glucose, serum creatinine and albumin/creatinine ratio (ACR) were evaluated, in addition, megalin expression was evaluated by western blot in renal cortex samples and in urinary extracellular vesicles, which were isolated from urine samples. The DI+EHPE group showed a significant reduction in blood glucose, serum creatinine and ACR compared to group D (p<0.05 for all). In addition, megalin expression in renal tissue and urine in the DI+EHPE group showed values close to those observed in the CTL group (p>0.05 for all). These results demonstrate that treatment with EHPE had a beneficial effect on preserving megalin expression in renal tissue, minimizing its urinary elimination.